Ascendis Pharma AS (ASND) Stock Forecast & Price Target
Ascendis Pharma AS · NASDAQ
$270.44-0.12 (-0.04%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 17 firms covering Ascendis Pharma AS, 17 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $254.00 to $355.00, so the covering firms are broadly aligned. The average target of $311.41 sits 15% above the current $270.44. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 16 to 17 over recent months. On the fundamentals, the Street sees revenue growth near 88% this year and 45% next, consensus EPS building from about $1.18 next quarter toward $8.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 ratings
Strong Buy
Strong Buy16%
Buy1694%
Hold00%
Sell00%
Strong Sell00%
Based on 17 analysts giving stock ratings to Ascendis Pharma AS.
As of Sep, 17 of 17 firms rate ASND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ASND EPS & revenue forecast
EPS · NEXT QUARTER
$1.18
Range $0.67 – $1.51 · 3 analysts
Next period, 3 analysts expect Ascendis Pharma AS to earn $1.18 a share (range $0.67 – $1.51), versus — a year earlier. Full-year consensus is $11.29, growing to $8.05 the year after.
REVENUE · NEXT QUARTER
$411.1M
Range $387.5M – $450.3M · 3 analysts · +68% YoY
Revenue is expected to reach $411.1M (range $387.5M – $450.3M), +68.0% year-over-year. Full-year consensus is $1.4B, rising to $2.0B next year.
Top analysts covering Ascendis Pharma AS
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ASND.
#1
Luca Issi
RBC Capital · Rank #1
Buy
$290.00+7.2% to target
Overall win rate
55%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Buy
No targeton ASND
Overall win rate
53%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$344.00+27.2% to target
Overall win rate
34%
+ Follow
#4
Li Watsek
Cantor Fitzgerald · Rank #275
Buy
$300.00+10.9% to target
Overall win rate
36%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #307
Buy
$312.00+15.4% to target
Overall win rate
37%
+ Follow
ASND stock forecast FAQ
What is ASND's average 12-month price target?+
The 17 analysts with a live target average $311.41 for Ascendis Pharma AS over the next 12 months, ranging from a $355.00 high to a $254.00 low.
Is ASND stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 17 analyst ratings, 17 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ASND?+
The Street-high target is $355.00 (Citigroup), and the Street-low is $254.00 (Cantor Fitzgerald). The average of all 17 active targets is $311.41.
How many Wall Street analysts cover ASND?+
17 analysts have an active rating on Ascendis Pharma AS, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering ASND?+
Among analysts who currently cover ASND, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $290.00 target.
What is Ascendis Pharma AS's projected EPS for next quarter?+
The consensus estimate is $1.18 per share (range $0.67 – $1.51) across 3 analysts. Full-year EPS is projected at $11.29, rising to $8.05 the following year.
How much revenue is Ascendis Pharma AS expected to report next quarter?+
Consensus revenue is $411.1M (range $387.5M – $450.3M). Full-year revenue is projected at $1.4B, growing to $2.0B next year.
Have analysts been upgrading or downgrading ASND lately?+
As of Sep, 17 of 17 firms rate ASND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ASND calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
